Summarized by Masters of Longevity from BioSpace - Funding.
Thryv closed $30 million to launch ASPIRE-HF and advance THRV-1268.
Key Takeaways
- Series B financing is led by InClin and existing investors.
- ASPIRE-HF is a Phase 2a trial in HFrEF with QTc prolongation.
- Wave II cohort enrollment was completed and no SAEs reported.
